______________________________________________________________________ 2 Understanding human bone marrow (BM) pathophysiology in the context of myelotoxic stress induced by drugs, radiation, or genetic mutations is of critical importance in clinical medicine. However, study of these dynamic cellular responses is hampered by the inaccessibility of living BM in vivo. Here, we describe a vascularized human Bone Marrow-on-a-Chip (BM Chip) microfluidic culture device for modeling bone marrow function and disease states. The BM Chip is comprised of a fluidic channel filled with a fibrin gel in which patient-derived CD34+ cells and bone marrow-derived stromal cells (BMSCs) are co-cultured, which is separated by a porous membrane from a parallel fluidic channel lined by human vascular endothelium. When perfused with culture medium through the vascular channel, the BM Chip maintains human CD34+ cells and supports differentiation and maturation of multiple blood cell lineages over 1 month in culture. Moreover, it recapitulates human myeloerythroid injury responses to drugs and gamma radiation exposure, as well as key hematopoietic abnormalities found in patients with the genetic disorder, Shwachman-Diamond Syndrome (SDS). These data establish the BM Chip as a new human in vitro model with broad potential utility for studies of BM dysfunction.
The human BM is the site where all adult blood cells originate and thus BM dysfunction causes significant patient morbidity and mortality. It is a major target of drug-and radiationrelated toxicities due to its high cell proliferation rates, and it is also affected by a variety of genetic disorders from congenital marrow failure syndromes to myeloid malignancies. While these abnormalities can be diagnosed and managed by monitoring peripheral blood counts, it is the proliferation and differentiation of hematopoietic cells in the marrow that is directly targeted in these disease states. Aside from invasive biopsies, there are no methods to study these responses in situ over time in human patients.
Various in vitro culture methods for human hematopoietic cells have been described, including culturing CD34+ hematopoietic progenitors in suspension (including methylcellulose-filled with a three-dimensional co-culture of human CD34+ cells and BMSCs in a fibrin gel while the bottom 'vascular' channel was lined by human umbilical vein endothelial cells (HUVECs) ( Fig. 1a) . The BM Chip was fed exclusively via medium perfusion through the vascular channel, analogous to the in vivo situation.
Over multiple weeks of culture, the CD34+ progenitors proliferated and coalesced to form a dense cellular microenvironment composed of multiple hematopoietic lineages, analogous to that observed in living BM ( Fig. 1a, Supplementary Fig. 1b) . The total number of cells present within the BM chip increased over 100-to 200-fold within 14 days of culture, after which cell numbers remained steady for 2 additional weeks (Fig. 1b) . The number of CD34+ cells also increased ~5-fold over the first 2 weeks but then decreased in number as multilineage differentiation increased at later times ( Fig. 1b) . Compared to BM Chip cultures, CD34+ cell suspension cultures supported the growth of similar numbers of total cells but contained fewer CD34+ cells and displayed decreased progenitor function over time, as measured by methylcellulose colony forming ability (Fig. 1b,c, Supplementary Fig. 1c ). Static fibrin gel cocultures of the same CD34+ progenitors and bone marrow stromal cells in BM Chips also contained fewer CD34+ cells over time, including immunophenotypically immature CD38-CD34+ cells (Supplementary Fig. 1d ).
Continuous myeloid and erythroid cell proliferation and differentiation in the BM Chip
Flow cytometric analysis and Wright-Giemsa staining showed that cells within the BM Chip were predominantly of the neutrophil and erythroid lineages, and they displayed the full spectrum of maturation states ( Fig. 2a,b, Supplementary Fig. 1e,f) . Other blood cell types were also produced, including megakaryocytes and macrophages, although they were present in fewer numbers ( Supplementary Fig. 1e,f) . Lymphoid-specific growth factors were not included in the culture medium and, as expected, no lymphoid differentiation was observed (data not shown).
To better assess the dynamics of on-chip hematopoiesis, cells were labeled with a 2 hour pulse of EdU just before they were harvested and analyzed at days 14 and 30. EdU+ cells within the neutrophil lineage appropriately resided largely within the immature CD16 lo population as opposed to the mature CD16 hi population (Fig. 2c) . Similarly, EdU+ cells of the erythroid lineage primarily exhibited an immature CD71+CD235-(E1) phenotype as opposed to a mature CD71-CD235+ phenotype (E3) ( Fig. 2d) . Importantly, EdU analysis at days 14 and 30 showed that the immature CD16 lo neutrophil and E1 erythroid cells maintained their proliferative nature over time ( Fig. 2c,d) . Furthermore, the proliferative fraction among total cells decreased as the BM Chip evolved to contain an increasing percentage of mature post-mitotic cells ( Supplementary Fig. 1g ) but the CD34+ population retained significantly higher EdU labeling, indicating continued CD34+ progenitor cell proliferation ( Supplementary Fig. 1g ).
In the course of these studies, we observed that a small fraction of cells spontaneously migrated or "intravasated" into the vascular channel over the first 2 weeks of culture, and these cells were markedly biased towards the myeloid lineage relative to the erythroid lineage when compared to cells remaining in the hematopoietic channel ( Supplementary Fig. 2a ). These intravasating cells also contained a 5-fold higher proportion of mature CD16 hi neutrophils ( Supplementary Fig. 2a ), which is reminiscent of the selective migration from marrow into peripheral blood by mature, but not immature, granulocytes that occurs in vivo. Importantly, plate-based cultures of CD34+ cells cannot mimic these effects and they also have known limitations with respect to diffusion-limited exchange of oxygen and nutrients, as well as removal of waste and soluble inhibitory factors 21 . In contrast, when we fabricated BM Chips using microfluidic devices that contained embedded oxygen sensors 22 , we found that oxygen levels remained constant at ~ 75% of atmospheric levels over 3 weeks in the BM Chip, whereas oxygen levels in static fibrin gel co-cultures containing the same cells dropped precipitously to near anoxic levels within the first week ( Supplementary Fig. 2b) . These findings confirm that the microfluidic BM Chip significantly improves oxygen delivery (and likely nutrient and waste exchange as well) compared to static plate-based cultures.
BM Chip predicts lineage-specific drug toxicities and marrow recovery upon withdrawal
BM toxicity is a significant dose-limiting side effect for many drugs. Hence, there is a great need for human in vitro models that can predict drug-induced myelosuppression at patient-relevant exposures and model the dynamics of marrow recovery from injury. To explore the utility of the BM Chip as a model of drug toxicity, we tested AZD2811, which is a selective small molecule inhibitor of Aurora B kinase that is currently in Phase I clinical development in an encapsulated polymer nanoparticle form. Interestingly, when AZD2811 was delivered by intravenous infusion as the rapidly converting phosphate prodrug barasertib, it was found to produce different myelotoxicity profiles when the same total dose was administered over either 2 or 48 hours in Phase I clinical trials for various malignancies 23, 24 . To mimic the infusion schedules used in those studies 23, 24 , we infused the vascular channels of BM Chips beginning after 10 days of culture with clinically relevant amounts of AZD2811 over 2 or 48 hours (total Area Under the Curve [AUC] of 0.5, 1, or 2 µM.h in both cases). These doses were calculated to deliver a range drug exposures that reach those observed in the plasma of human patients who exhibited cytopenias 24 (see Methods for details). The attainment of patient-relevant dosing in terms of AUC and overall shape was confirmed by comparing direct measurements of AZD2811 concentrations in BM Chip outlet medium, pharmacokinetic (PK) models of BM Chip exposures based on those measurements, and the simulated free AZD2811 concentration profiles in the plasma of an average patient (based on its known PK properties) at a range of clinical doses 24 ( Fig. 3a, Supplementary Fig. 3 ).
Importantly, flow cytometric analysis revealed that the 2-hour and 48-hour infusions had different effects in the BM Chip. Dose-dependent toxicity in the erythroid lineage was greater following the 2-hour infusion regimen ( Fig. 3a) , which closely aligns with clinical data where anemia (CTCAE grade ˂ 3) was only reported as an adverse event in patients receiving the 2hour infusion of barasertib 23, 24 . In contrast, dose-dependent toxicity of the neutrophil lineage in the BM Chip appeared to be greater with the 48-hour infusion ( Fig. 3a) than the 2-hour infusion (68% vs. 48% decrease at the highest tested dose; p < 0.001). This is also consistent with published clinical data showing a higher incidence of severe neutropenia (CTCAE grade ≥ 3) with drug infusions over 48 hours versus 2 hours at a given AUC 23, 24 . Importantly, suspension cultures of the same CD34+ cells failed to reproduce the regimen-dependent erythroid toxicity (anemia) profile that was mimicked by the human BM Chip (Supplementary Fig. 4a ).
Clinical trial data show that the hematologic side effects of barasertib were readily managed by withholding drug or stimulating with growth factors 23, 24 , indicating that efficient marrow recovery occurs when administration of AZD2811 is ceased. Similarly, when we cultured the human BM Chip in drug-free medium for 7 additional days after administering the highest dose of AZD2811 (2 µM.h), we observed robust neutrophil recovery with both the 2 and 48-hour dosing regimens as well as erythroid recovery with the 2-hour regimen ( Fig. 3b,   Supplementary Fig. 4b ). In contrast, this level of neutrophil recovery was not seen in platebased CD34+ suspension cultures (Fig. 3b) . These results suggest that the BM Chip could be used to model a full cycle of BM injury and recovery during preclinical drug evaluation and development, which up to now has required animal studies.
Effects of drugs and ionizing radiation on mature versus immature hematopoietic cells
Aurora B kinase, the pharmacological target for AZD2811, is necessary for the proper alignment and segregation of chromosomes during mitosis as well as completion of cytokinesis 25 . Thus, inhibition of this kinase by AZD2811 should preferentially damage immature dividing precursors while sparing mature post-mitotic cells. Aside from doing a marrow biopsy, it would be difficult to assess this response in patients; however, we are able to test this directly in the human BM Chip. Indeed, the effect of AZD2811 was significantly greater on immature CD16 lo neutrophil precursor cells than on mature CD16 hi neutrophils with both dosing regimens ( Fig. 4a) . Furthermore, the anemia-inducing 2-hour infusion regimen caused preferential toxicity in early E1 erythroid progenitors versus more mature E3 erythroid cells (Fig. 4b) .
The maturation-dependent effects we observed in response to drug exposure also would be predicted to occur in response to other types of myelotoxic stress, such as ionizing gamma ()-radiation. To test this, we exposed BM Chips to ionizing radiation doses ranging from 1 Gray (Gy), for which total body irradiation in humans results in mild recoverable cytopenias, to 4 Gy which causes 50% lethality over 60 days in the absence of supportive care 26 . BM Chips exposed to these levels of -radiation showed mildly decreased cell numbers at 1 Gy and severe toxicity at 4 Gy, matching human radiation sensitivities, and also displayed the predicted preferential toxicity of immature precursors as assessed by neutrophil, erythroid, and CD34+ cell numbers ( Fig. 4c, Supplementary Fig. 4c ). The responses of the BM Chip to AZD2811 and radiation-induced injury demonstrate that it can accurately predict nuanced hematopoietic toxicities with similar sensitivities seen in human patients caused by marrow stressors targeting disparate molecular pathways.
Modeling Shwachman-Diamond Syndrome in the human BM Chip
Shwachman-Diamond Syndrome (SDS) is a genetic bone marrow failure syndrome which may also affect other organ systems, particularly the exocrine pancreas 27, 28 . The majority of patients harbor biallelic mutations in the SBDS gene. The bone marrow is typically hypocellular for age and neutropenia (found in almost all patients) is the most common hematologic abnormality 29 . Hematologic dysfunction may involve other lineages (e.g. thrombocytopenia or anemia) and there is a predisposition to developing myeloid malignancies as well 27, 28 . The study of hematopoiesis in the context of SDS has been limited because animal models do not faithfully recapitulate the human disease [30] [31] [32] [33] [34] . To assess the ability of the BM Chip to phenocopy the hematopoietic defects of SDS, we cultured CD34+ cells from two SDS patients ( Supplementary Fig. 5a ) together with normal BMSCs and endothelial cells in the 2channel microfluidic device.
After 2 weeks of culture, SDS BM Chips displayed both broad defects in hematopoiesis and cell-type specific responses. Overall, significantly fewer cells developed in the SDS BM Chip compared to control BM Chips ( Fig. 5a, Supplementary Fig. 5b) , analogous to the hypoplastic phenotype often observed in SDS patient marrow biopsies 27, 29 . This decrease in cell numbers was present in both the neutrophil and erythroid lineages ( Fig. 5b) . Maintenance of CD34+ cell numbers in the SDS BM Chip was also impaired ( Fig. 5c) , consistent with an intrinsic defect in CD34+ progenitor function in SDS patients, which reinforces existing literature that has demonstrated their impaired colony forming ability 35, 36 . We noticed that neutrophils in the SDS BM Chip displayed an aberrant maturation pattern ( Fig. 5d, Supplementary Fig. 5c ).
In contrast, no maturation defect was observed in the erythroid lineage, evidenced by similar numbers of mature (E3) erythroid cells in SDS and control BM Chips (Fig. 5e ). Instead, there was an unexpected loss of early (E1) erythroid progenitors (Fig. 5e ), and this was consistent between the two different SDS patients. Further study is needed to determine the generality and implications of these findings but these data demonstrate that SDS BM Chips display multiple hematopoietic abnormalities that parallel the clinical manifestations of neutropenia, anemia, and bone marrow failure in this disease.
Discussion
Taken together, our data show the microfluidic human BM Chip models key aspects of human hematopoiesis by supporting erythroid differentiation as well as myeloid development and mobilization over 1 month of culture while improving maintenance of CD34+ progenitors over traditional culture methods. The BM Chip was able to recapitulate the lineage-specific and maturation-dependent toxicity responses of human marrow to AZD2811 and ionizing radiation at human-relevant exposures. Finally, BM Chips seeded with SDS patient-derived CD34+ cells demonstrated hematopoietic dysfunctions that parallel key hematologic abnormalities observed in patients with Shwachman Diamond Syndrome.
It is worth noting that this study does not address issues of hematopoietic stem cell (HSC) presence or maintenance. Methods to effectively support, expand, or even create HSCs in vitro are active areas of investigation and would represent a milestone in hematopoietic culture systems 1,2,10,37-39 . This work, however, was directed towards creating an enabling technology with near-term translational potential as an effective model of human marrow pathophysiology. As the primary function of the bone marrow in vivo is the production of blood cells, we sought to balance proliferation, multilineage differentiation, and continued progenitor survival. In doing so, we were able to achieve extended myeloerythroid proliferation and maturation while also improving bulk CD34+ cell maintenance.
Microfluidic culture offers multiple advantages over conventional static culture methods, including improved nutrient exchange and waste removal. We found that the BM Chip, unlike a static gel culture, was able to maintain stable oxygen levels over time. Oxygen tension has been shown to play an important role in hematopoietic cell biology 40 . And while the experiments in this study were performed under atmospheric oxygen conditions, the ability to control oxygen levels enables future studies that match experimental oxygen tensions with those found in in vivo microenvironments [41] [42] [43] .
Careful consideration was given to how to best model Shwachman Diamond Syndrome given the limited availability of primary patient-derived cells. Ultimately, BM Chips were set up using SDS CD34+ cells but normal BMSCs as opposed to using BMSCs from SDS patients.
This limited potential variability and allowed a better comparison to BM Chips seeded with normal CD34+ cells and BMSCs. Data obtained with this approach demonstrated interesting cell-intrinsic defects of CD34+ progenitors from SDS patients, which are known to play a central role in SDS pathology because hematopoietic stem cell transplant cures the marrow phenotype in SDS 28 . However, future experiments could examine possible contributions of the stromal microenvironment, which is a subject of active investigation in the field 31, 35, 44 .
Relatively little is known about how SBDS mutation affects the differentiation of human hematopoietic cells in the marrow. The impaired neutrophil maturation we observed in the SDS BM Chips aligns with prior work showing impaired function of peripheral blood neutrophils in SDS patients 36, 45, 46 and it is also supported by results from SDS inhibition and knockout studies in mice 32, 33 . The decrease in erythroid precursors was unanticipated, given that neither patient had clinically documented anemia. Nevertheless, the finding was consistent between two patients with different genetic abnormalities. It is possible, in light of a prior study showing impaired erythroid development upon SBDS knockdown in normal and immortalized human cells 47 , that increased erythropoietic stress may be a feature of hematopoietic dysfunction in SDS. However, further study is needed to confirm the physiologic significance of these data.
In summary, the vascularized human BM Chip represents a new in vitro model of human hematopoiesis that recapitulates many clinically relevant features of bone marrow pathophysiology in response to drugs, ionizing radiation, and genetic mutation. Future use of the BM Chip may reduce the incidence of unexpected myelotoxicity in the drug discovery process and the use of chips containing patient-derived cells could advance personalized medicine for patients with genetic BM failure disorders. This technology could also prove valuable in the study of a broader variety of marrow pathologies for which there are no current effective models.
METHODS

Chip fabrication and preparation
The device was fabricated using polydimethylsiloxane (PDMS; SYLGARD® 184 silicone elastomer kit) with previously described soft lithography techniques 19, 48 or obtained from Emulate, Inc. The chip design, which was similar to previously published devices 19 , included apical and basal microchannels with dimensions of 1 × 1 × 16.7 mm and 1 × 0.2 × 16.7 mm (w x h x l), respectively, that were separated by a 50 μm thick porous PDMS membrane (7μm diameter holes with 40μm spacing). Both channels were washed with 70% ethanol, filled with 0.5 mg/mL sulfo-SANPAH solution (Thermo Fisher Scientific, A35395) in 50mM HEPES pH 8
and placed under a UV lamp (Nailstar, NS-01-US) for 20 minutes to activate the surface.The microchannels were then rinsed sequentially with 50 mM HEPES buffer and cold PBS, and then filled with a coating solution of PBS containing 100 μg/ml fibronectin (Gibco, 33016-015) and 50 μg/ml collagen (Sigma, C2249) and placed at 37°C for 2 hours. The solution was then aspirated from the chip and it was allowed to air dry overnight.
Organ Chip Culture
The apical channel was first seeded with 1x10 4 primary human CD34+ cells and 5 x10 3
BMSCs in a solution containing 5 mg/ml fibrinogen (Millipore, 341578), 0.2 mg/ml collagen I (Sigma, C2249), 25 μg/ml aprotinin (Sigma, A3428), and 0.5 U/ml thrombin (Millipore, 605195), that was allowed to gel on-chip. To prevent premature crosslinking, medium containing fibrinogen and aprotinin was prepared separately from the medium containing cells, collagen, and thrombin. The two solutions were then carefully mixed at a ratio of 1:3 (vol:vol) to avoid bubbles, immediately pipetted into the apical channel (25uL per chip), and allowed to gel for 20-30 minutes at room temperature. HUVECs (Lonza, CC-2517 or C2519A) were seeded either at this point or at day 8 by adding medium containing the cells (2-3x10 6 /ml; 30uL/chip) into the lower fibronectin-and collagen-coated channel followed by immediate inversion of the device and static incubation at 37°C for 2 hours to promote adhesion to the central membrane. The devices were then placed right-side up and apical channel ports were sealed with sterile tape.
The entire BM Chip was then fed via medium perfused only through the endothelium-lined channel using a 16-channel peristaltic pump (Ismatec, ISM 938D) with 0.25 mm inner diameter (ID) pump tubing (Ismatec, 95723-12) with 19G bent metal pins at 1.42-1.6μL/min (pump speed varied depending on manufacturer's lot of tubing). Outflow medium was collected using 0.89 mm ID tubing (Cole-Parmer, 95809-26) with 19G bent metal pins into a sterile reservoir. All parts were sterilized using oxygen plasma (Diener ATTO; 0.3 mbar pressure, 50W power and 2 min plasma time). Pumps were set to intermittent flow and pushed at 200 μL/day for the first seven days and 400μL/day thereafter. For drug studies, the volume was increased to 1.6 mL/day when drug treatment was initiated.
In all studies, we used SFEM II medium (STEMCELL Technologies, 09655) 
Static gel and suspension cultures
For static gel cultures, the same numbers of CD34+ cells and BMSCs as used in the BM Chips were seeded into individual wells of a 96 well plate (Corning, 353072) in 50μL of the same fibrin gel in order to cover the entire well surface. After crosslinking, 200μL of medium was added on top of the gel; the medium was fully replaced on day 3 and then daily starting at day 5.
For suspension cultures, the same numbers of CD34+ cells were seeded into individual wells of a 96 well plate in 250μL of medium, and 50% of the medium volume was replaced daily.
Oxygen measurements
BM Chips with embedded oxygen sensors were created as recently described 22 . For static gel culture measurements, an oxygen sensor spot (PreSens Precision Sensing GmbH, SP-PSt3-NAU) was placed at the bottom of a 96 well flat bottom plate before cell seeding. Cells were then cultured as described above. Oxygen measurements were optically measured daily using an OXY-4 mini instrument (PreSens Precision Sensing GmbH). . A representative gating strategy is described in Supplementary Fig. 6 . 
Hematopoietic CD34+ cell isolation
Immunofluorescence microscopy
Cell growth assay
Growing cells were detected using the Click-iT™ Plus EdU Alexa Fluor™ 350 Flow
Cytometry Assay Kit (Thermo Fisher Scientific, C10645). BM Chips were perfused with medium containing 10μM EdU for 2 hours immediately before cell harvesting as described above. After surface staining with panel 1 antibodies, samples were fixed with 100 μl of 2% paraformaldehyde (Electron Microscopy Sciences, 15730), 25mM HEPES (Thermo Fisher Scientific, 15630-080) in DPBS (Gibco, 14190-144) for 20 min at room temperature. Samples were then processed as per manufacturer's protocol. 
Wright-Giemsa staining
Drug treatment
AZD2811 (formerly known as AZD1152 hydroxy-quinazoline pyrazole anilide) was provided by AstraZeneca in DMSO and stored at -20°C. Fresh medium with drug at the indicated concentrations was prepared daily and added to BM Chip reservoirs and plate cultures for the indicated times. To stop drug treatment, BM Chips were flushed at maximum pump speed (using the MAX/CAL button) for 30 seconds while suspension cultures were harvested, diluted with additional medium, centrifuged at 300g for 10 min, and replated in fresh medium.
Dosing was based on results from a Phase I clinical trial 24 , which showed that cytopenia- 
PK modeling and simulation
All model fitting and simulations were performed using WinNonlin Phoenix NLME 6.4A. For the BM Chip, a three-compartment PK model was fitted to the LC-MS/MS quantified AZD2811 concentrations. The central compartment in the model was viewed as representing the vascular channel and therefore the volume was fixed at the physical volume of the channel (20 µL) and the clearance fixed at the flow rate of medium through the channel (72 µL/hr). The first peripheral compartment was viewed as representing the hematopoietic channel and the volume fixed at the physical volume of the channel (25 µL). The rate and extent of distribution into the hematopoietic channel was described using a distribution clearance (Cl2) and a partition coefficient (Kphem) with both parameter value estimates being obtained during the model fitting process. Distribution into a second peripheral compartment (described by parameters V3 and Cl3) was found to be required to describe the second phase in the outlet medium concentration profile during the washout of drug from the system. Model parameter value estimates (Kphem = 4.5; Cl2 = 99 mL/hr; V3 = 163 µL; Cl3 = 5.6 µL/hr) were derived by fitting the PK model to the combined outlet medium concentration data from all AZD2811 dosed BM Chips using a naïvepooled approach. Residual unexplained variability (between model and observed concentration data) was modelled using a multiplicative error model.
Radiation exposure
For radiation exposure studies, BM Chips were disconnected from peristaltic pumps, transported in sterile containers to an irradiation facility at Boston Children's Hospital, and exposed to a single selected γ-irradiation dose (Cs-137; Gammacell 40 Exactor) at 0.98 Gy/min. BM Chips were then reconnected to the peristaltic pumps, flushed for 5 seconds at maximum pump speed to remove bubbles, and placed in the incubator. 100ng/mL Flt3 (AF-300-19-50UG), 100ng/ml SCF (AF-300-07-50UG), 100ng/ml TPO (AF-300-18-50UG), 20ng/ml IL3 (AF-200-03-50UG). After 30-32 hours of recovery, CD34+ cells were sorted using magnetic beads as above and cultured in the BM Chip as described before.
Shwachman-Diamond Syndrome CD34+ cells
Statistical Analyses
All graphs depict mean ± standard deviation (s.d.) and tests for differences between two groups were performed using two-tailed unpaired Student's t-test. Prism 7 (GraphPad Software) was used for statistical analysis. cell numbers determined using flow cytometry in BM Chips that were matured for 10 days, exposed to varying doses of ionizing radiation (0,1, 2, or 4 Gy), and then sacrificed at day 14.
Note that radiation exposure preferentially reduced the numbers of immature CD16 lo neutrophil (left) and immature (E1) erythroid cell subpopulation (middle) compared to the more differentiated CD16 hi and E3 populations (n=7 chips; data pooled from 2 independent experiments; *P<0.05; **P<0.01; ***P<0.001). Supplementary Fig. 1 | a Fig. 2 | a (2µM.h), and then allowed to recover in drug-free medium. Analysis was performed at days 10, 12, and 19 (n=6 chips per condition at each timepoint; data pooled from 2 independent experiments). c, Total cell numbers in BM Chips that were matured for 10 days, irradiated with 0, 1, 2 or 4 Gy, and sacrificed at day 14 (n=7 chips, data pooled from 2 independent experiments; *P<0.05; **P<0.01; ***P<0.001). Fig. 5 | a 
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